DIPG-61. RESCUE REGIMENS AFTER BIOMEDE: POSSIBLE INFLUENCE ON OS ASSESSMENT

BIOMEDE is a multicentric randomized phase II trial to evaluate in DIPG the OS of patients treated with dasatinib, erlotinib or everolimus. The OS is the result of the first line treatment but it could also be affected by re-irradiation and the second line treatment received after progression, espec...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Carlo, Daniela Di, Pommier, Bertille, Teuff, Gwenael Le, Abbou, Samuel, Berlanga, Pablo, Geoerger, Birgit, Puget, Stephanie, Beccaria, Kevin, Blauwblomme, Thomas, Debily, Marie-Anne, Castel, David, Lechapt, Emmanuelle, Varlet, Pascale, Dangouloff-Ros, Volodia, Boddaert, Nathalie, Vassal, Gilles, Deley, Marie-Cécile Le, Grill, Jacques
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2020
Fag:
Diffuse Midline Glioma/DIPG
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715765/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.106
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker